Abstract Constitutional mismatch repair deficiency syn-
Introduction
Constitutional mismatch repair deficiency syndrome (CMMRD) is a rare autosomal recessive predisposition to colorectal polyposis and a wide spectrum of malignancies, including hematological malignancies and brain tumors, often childhood-onset [1, 2] . Strikingly, CMMRD is caused by biallelic inheritance of mutations in the mismatch repair genes (MMR), which cause Lynch syndrome in a heterozygous state. Therefore, carrier parents of individuals with CMMRD will themselves have Lynch syndrome [3] .
Of the four MMR genes MLH1 (OMIM 120436), MSH2 (OMIM 609309), MSH6 (OMIM 600678), and PMS2 (OMIM 600259), most reported cases of CMMRD are due to biallelic inheritance of mutations in PMS2 followed by MSH6 [1] . Interestingly, the clinical phenotype of Lynch syndrome patients with heterozygous MSH6 and especially PMS2 mutations is much less severe than those of patients with classic Lynch syndrome, with an estimated 10-19 % lifetime risk for colorectal cancer (CRC) and 11-24 % for endometrial cancer with PMS2 mutations [4] [5] [6] . In addition, individuals with CMMRD caused by biallelic PMS2 mutations often have limited or no family history of cancer [1] . Here, we describe a patient with a clinical CMMRD phenotype whose genetic testing identified a known PMS2 pathogenic mutation (InSiGHT class 5) and a novel PMS2 missense mutation, called a variant of uncertain significance (VUS) by the CLIA testing laboratory (InSiGHT class 3) [7] . Written informed consent was obtained from the participant in this case report for additional molecular analysis and presentation of the case.
Patient and methods

Case report
The patient, a Caucasian female, initially presented to our institution at age 17 for surgical consultation and genetic counseling due to her personal history of multiple colon adenomas. She experienced rectal bleeding and abdominal cramping and underwent a colonoscopy that identified multiple polyps throughout the colon, many of them diminutive; 15 were biopsied and shown to be adenomas. Upper endoscopy identified fundic gland polyps with lowgrade dysplasia. A detailed pedigree was taken and revealed no family history of polyposis. Her mother had not undergone colonoscopy and her father had a history of two polyps at age 42. The patient reported one brother in good health. The only cancer reported in the family was late-onset CRC in two brothers of the patient's maternal great-grandmother and CRC in her paternal great-grandfather (Fig. 1a) . The patient underwent comprehensive germline APC testing followed by MUTYH testing; both were normal.
The patient underwent restorative proctocolectomy with J-pouch ileorectal anastomosis. Pathology review of the surgical specimen revealed a 2 mm focus of invasive moderately differentiated adenocarcinoma involving the superficial submucosa arising from a 3 cm tubulovillous adenoma with high-grade dysplasia in the rectum and at least 20 synchronous adenomas. Thirty-eight lymph nodes were examined with no cancer present, thus rendering a diagnosis of stage I rectal cancer. Immunohistochemistry (IHC) for the MMR proteins was not performed in the rectal tumor due to insufficient tissue.
On a follow-up CT scan 1 year after surgery, the patient was identified to have a 4 cm retroperitoneal lymph node. Fine needle aspiration was consistent with metastatic poorly differentiated mucinous adenocarcinoma with signet ring cells. The patient underwent retroperitoneal lymphadenectomy and the IHC revealed intact expression of the four MMR proteins; however, microsatellite instability analysis (MSI) by PCR was not performed due to insufficient tissue.
The patient was followed for post-cancer surveillance at our center and at age 23 she was identified to have stage IA clear cell carcinoma of the endometrium. She underwent a total abdominal hysterectomy and bilateral salpingooophorectomy.
In light of the patient's diagnosis of endometrial cancer, she was re-referred to genetic counseling. Due to concern for CMMRD, genetic testing of the MMR genes was ordered. The patient was identified to have one known pathogenic mutation in PMS2, described as c.1831insA (p.Ile611Asnfs*2), and an additional PMS2 alteration , that was classified as a VUS by the performing CLIA laboratory. Furthermore, the patient describes a large café-au-lait macule involving her lower limb and buttock. This clinical phenotype received a score C3, meeting the recently-proposed indication criteria for CMMRD testing [2] .
The patient's parents both underwent single-site testing for these alterations; her mother was found to be the carrier of the c.1831insA PMS2 mutation and her father was found to be the carrier of the c.505C[G PMS2 VUS, confirming that these alterations are in trans in the proband.
Germline and tumor genetic testing results
We confirmed the presence of both germline PMS2 alterations in the laboratory by LR-PCR followed by exon specific PCR and sequencing as previously described (Fig. 1b) [8] . The c.1831insA (p.Ile611Asnfs*2) alteration is a frameshift mutation located in exon 11 and is consistent with a pathogenic mutation, which has been reported previously in two Lynch syndrome patients [5] . However, the PMS2 c.505C[G (p.Arg169Glu) variant has not been reported before, although by in silico analysis it is predicted to generate a missense change in an amino acid residue highly conserved and located close to the ATP binding region. This alteration is classified as probably damaging by the Polyphen, SIFT and CONDEL bioinformatics algorithms [9] [10] [11] . Then, we reviewed the immunohistochemistry of available tumor sites (retroperitoneal lymph node and large tubulovillous adenoma) and normal tissues, revealing intact staining of the MMR proteins (including PMS2). In addition, we performed MSI analysis in an additional adenomatous polyp with highgrade dysplasia included in the original colorectal resection, which was available for testing, revealing high-level of MSI in eight of ten markers (Fig. 2a, b) .
The presence of CMMRD was confirmed by germline MSI (gMSI) analysis that was performed in two germline DNA controls (NA12832 and NA10846) from NIGMS Human genetic cell repository (Coriell Institute, NJ, USA) and germline DNA of the patient using 3 dinucleotide microsatellites (D17S791, D2S123, and D17S250) as previously described [12] . The gMSI ratios for D2S123, D17S250 and D17S791 in our CMMRD patient were 0.153 (0.145-0.156), 0.156 (0.154-0.161) and 0.276 (0.258-0.281), respectively, and for the DNA controls were 0.04 (0.039-0.041), 0.049 (0.048-0.051), and 0.032 (0.028-0.034), respectively. Therefore, the ratios in the patient were higher than those showed in the controls and were also within the diagnostic range for CMMRD (Fig. 2c ) [12] .
Discussion
The c.505C[G PMS2 alteration was identified in trans with a known PMS2 pathogenic mutation in our patient with strong clinical and molecular evidence of CMMRD. Therefore, it is possible that this PMS2 VUS (InSiGHT class 3) is contributing to our patient's clinical phenotype. Patients presenting with one pathogenic MMR mutation in trans with a VUS is a common clinical presentation among patients with CMMRD [13] . While the co-occurrence of a 
pathogenic mutation in conjunction with a VUS in a patient with CMMRD does not provide sufficient and definitive evidence on the pathogenicity of the VUS, it does raise the possibility that this alteration is responsible for the patient's phenotype. Our patient has strong clinical evidence of CMMRD, including young-onset colorectal polyposis and endometrial cancer. In addition, her gMSI testing demonstrated the presence of genomic instability in peripheral blood, and along with the phenotype, it is consistent with a CMMRD diagnosis. Furthermore, functional validation assays using lymphoblastic cell lines (LCLs) to detect ex vivo MSI have been recently described as the gold standard for confirmation of pathogenicity of genetic alterations (including VUS) in the context of CMMRD [13] ; however, LCLs were not available in our patient for additional testing.
The PMS2 c.505C[G novel VUS is likely to have functional consequences in the MMR pathway. In fact, the patient's presentation is most consistent with CMMRD rather than a heterozygous PMS2 alteration, which would be expected to cause a modest increased risk for later-onset Lynch syndrome cancers without polyposis. In addition, results derived from bioinformatics analysis are consistent with a lack of functionality in the protein secondary to this alteration. Furthermore, a heterozygous frameshift mutation such as c.1831insA would be expected to cause absence of PMS2 protein staining upon acquisition of a second somatic hit inactivating the remaining PMS2 allele, as has been reported previously in several patients with this specific PMS2 alteration [5, 14] . However, in the present case, a possible explanation for the intact staining of PMS2 in the patient's malignancies could be that the second PMS2 alteration, c.505C[G, results in a stable but nonfunctional protein, thus leading to positive staining in the tumor. This phenomenon of mutations causing intact IHC staining has been reported previously [15] . Another possibility is that this alteration may represent a hypomorphic allele rather than a classic pathogenic mutation, similar to a PMS2 founder mutation recently described in the Inuit population, thus causing attenuated CMMRD in the homozygous state but maintenance of mismatch repair activity in the heterozygous state [16] . Finally, an alternate explanation for our patient is the presence of an undetectable second pathogenic PMS2 mutation; this gene is well-known for its complexity of analysis [8] . Ultimately, determining the functional impact of this VUS is critical to making recommendations for families harboring it. In the present case, we recommended a conservative approach with enhanced colon surveillance in the patient's father, who also carried the VUS, and made recommendations for germline testing of both the pathogenic PMS2 mutation and VUS in the patient's brother. However, additional analyses including multifactorial likelihood models, segregation studies, and functional analysis based on MSI determination and tolerance to methylation in LCLs [13] are still needed to provide definitive evidence of the pathogenicity of this VUS. In summary, this case provides a novel description of the c.505C[G (p.Arg169Glu) VUS in a patient with CMMRD.
